Roche Discount Fails to Win Breast-Cancer Drug U.K. Backing

  • NICE says NHS can't afford Roche's Kadcyla in final decision
  • Patients taking Kadcyla don't have to stop taking it

Roche Holding AG failed to win the endorsement of the U.K.’s health-cost regulator for its breast-cancer medicine Kadcyla, capping two years of haggling over the cost of the treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.